Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Certican · 2 trials · 2 indications
Progression of Interstitial Fibrosis/Tabular Atrophy (IF/TA) is the percentage (%) of participants with an increase \>= 1 in IF/TA grade according to Banff (2005 - 2007)according to Epithelial-mesenchymal transition (EMT) profile and by treatment groups. Grade I (the better): mild interstitial fibrosis and tubular atrophy (\<25% of cortical area) Grade II : moderate interstitial fibrosis and tubular atrophy (26-50% of cortical area) Grade III (the worse) : severe interstitial fibrosis and tubular atrophy (\>50% of cortical area)
| Arm | Type | Description |
|---|---|---|
| Certican EMT+ | EXPERIMENTAL | Patients randomized to the Certican® treatment group started this treatment after randomization (which took place 3 to 4 months post-transplantation), preferably in the evening, otherwise the following morning. Patients in the Neoral® treatment group did not receive Certican®. |
| Certican EMT- | EXPERIMENTAL | Patients randomized to the Certican® treatment group started this treatment after randomization (which took place 3 to 4 months post-transplantation), preferably in the evening, otherwise the following morning. Patients in the Neoral® treatment group did not receive Certican®. |
| Neoral EMT+ | ACTIVE_COMPARATOR | Between transplantation and randomization, all patients have received Neoral®. Treatment had to be initiated within 24 hours post-transplantation in combination with Myfortic®. |
| Neoral EMT- | ACTIVE_COMPARATOR | Between transplantation and randomization, all patients have received Neoral®. Treatment had to be initiated within 24 hours post-transplantation in combination with Myfortic®. |
| Name | Type | Description |
|---|---|---|
| Certican® | DRUG | Certican® was supplied to the participating centers by Novartis for the whole duration of the study in the form of tablets containing 0.75, 0.5 and 0.25 mg and packaged in blister packs. |
| Neoral | DRUG | Neoral® was also supplied to participating centers for the entire duration of the study in the form of soft capsules of 10 mg, 25 mg, 50 mg and 100 mg, and packaged in blister packs. |
| Myfortic | DRUG | Myfortic ® was supplied to the participating centers for the duration of the study in the form of 180 and 360 mg gastro-resistant, film-coated tablets. Myfortic® treatment was provided to patients preoperatively or within 24 hours post-transplantation according to the practices of the center. The starting dose was generally 1,440 mg/day, in 2 daily oral fractions, administered at 12 hour intervals up to randomization. Depending on the practices of the center and for the first 6 weeks post-transplantation, a maximum daily dose of 2160 mg of Myfortic® could be administered. In the Neoral® group, the daily dose of 1440 mg was maintained throughout the study. In the Certican® group, the dose was halved (i.e. 720 mg/day) on introducing Certican® and maintained at 720 mg/day until the end of the study. An increase in the daily dose of Myfortic® (in the Certican® group) was not authorized unless this was a temporary increase that did not exceed a period of 14 consecutive days. |
| Simulect® | DRUG | The administration of Simulect® was part of the standard immunosuppressant therapy. This induction therapy was provided to patients in the form of commercial ampoules each containing 20 mg. Simulect® was administered to each patient at the dose of 20 mg on D0 and D4 post-transplantation. |
| Corticosteroids | DRUG | An intravenous steroid treatment could be administered peri or intraoperatively according to local practice at each center. Oral steroid treatment was quickly introduced (in the week following transplantation) at a daily dose of 20 mg and was then reduced and continued throughout the study at a minimum dose of 5 mg/day. |
| Certican | DRUG | - |
Inclusion Criteria: * Recipient of a primary or secondary deceased or living (related or not) donor kidney transplant and who requires basiliximab induction therapy. * Cold ischemia time \< 30 hours. * Women of child-bearing age, even those with a history of infertility, must have had a negative pr...
Certican is used in kidney transplantation and for renal interstitial fibrosis. It is being investigated for use in pediatric de novo renal transplant patients and in adult de novo renal transplant recipients to assess the progression of renal interstitial fibrosis and tubular atrophy.
Certican is developed by Novartis AG, which trades under the ticker NVS. The company is conducting clinical trials to evaluate the drug's safety and efficacy in renal transplant settings.
Certican is in Phase 3 clinical development. It is an investigational small molecule being studied for kidney transplantation and renal interstitial fibrosis, and it is not yet approved by regulatory authorities.
Certican has been studied in two completed Phase 3 trials: NCT00098241, which evaluated safety and efficacy in pediatric de novo renal transplant patients, and NCT01079143, which assessed progression of renal interstitial fibrosis and tubular atrophy in adult de novo renal transplant recipients.
Certican is a small molecule that works by inhibiting the mammalian target of rapamycin (mTOR), a key regulator of cell growth and proliferation. By blocking mTOR, Certican suppresses the immune response that can lead to organ rejection in transplant patients.